State-of-the-Art Review: Pharmacology and Pharmacokinetics of Antithrombotic Agents

Clinical and Applied Thrombosis/Hemostasis

Volumn 3, Issue 3, 1997, Pages 157-164

  Kandrotas, Robert J ^a  

^a MIAMI CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84996231989     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969700300302     Document Type: Review

References (87)

1. Vermylen J., Verstraete M., Fuster V. Role of platelet activation and fibrin formation in thrombogenesis. J Am Coll Cardiol 1986; 8: 2B.
2. Zucker MB, Nachmias VT Platelet activation. Arteriosclerosis 1985; 5: 2.
3. Unkeless J., Dano K., Kellerman G., et al. Fibrinolysis associated with oncogenic transformation. Partial purification and characterization of cell factors, a plasminogen activator. J Biol Chem 1974; 249: 42-95.
4. Schoefield FW A brief account of a disease of cattle simulating hemorrhagic septicaemia due to feeding sweet clover. Can Vet Rec 1922; 3: 74.
5. Jackson CM, Suttie JW, Recent developments in understanding the mechanism of vitamin K and vitamin K-antagonist drug action and the consequences of vitamin K in blood coagulation. Prog Haematol 1977; 10: 333-339.
6. Bell RG, Matschiner RJ Warfarin and the inhibition of vitamin K activity by an epoxide metabolite. Nature 1972; 237: 32-33.
7. Whitlon DS, Sadowski JA, Suttie JW Mechanism of coumarin action and significance of vitamin K-epoxide reductase inhibition. Biochem 1978; 17: 1371-7.
8. O'Reilly RA, Aggler PM Studies on coumarin anticoagulant drugs: Initiation of warfarin therapy without a loading dose. Circalation 1968; 38: 169-173.
9. Lewis RJ, Trager WF, Chan KK, et al. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974; 53: 1607-1617.
10. O'Reilly RA Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974; 16: 348-354.
11. Breckenridge AM, Orme M. Kinetics of warfarin absorption in man. Clin Pharmacol Ther 1973; 14: 955-961.
12. Bell RG Mechanism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K-epoxide cycle. Fed Proc 1978; 37: 2599-2604.
13. Holford Nhg. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483-504.
14. O'Reilly RA, Kowitz PE Studies on the coumarin anticoagulant drugs: Interaction of human plasma albumin and warfarin sodium. J Clin Invest 1967; 46: 829-837.
15. O'Rielly RA Interaction of several coumarin compounds with human and canine plasma albumin. Mol Pharmacol 1970; 7: 209-218.
16. Yacobi A., Levy G. Protein binding of warfarin enantiomers in serum of humans and rats. J Pharmacokinet Biopharm 1977; 5: 123-131.
17. Soloman H., Schrogie J. The effect of various drugs on the binding of warfarin-14C to human albumin. Biochem Pharmacol 1967; 16: 1219-1226.
18. Sutcliffe FA, MacNicoll AP, Gibson GG Aspects of anticoagulant action: a review of pharmacology metabolism and toxicology of warfarin and congeners, Drug Metab Drug Int 1987; 5: 225-272.
19. Seller EM, Koch-Wesser J. Interaction of warfarin stereoisomers with human albumin. Pharmac Rec Commun 1975; 7: 331-339.
20. Testa B. Regio-and stereoselectivity in drug metabolism: two examples. Pharm Int 1981; 2: 34-37.
21. Lewis RJ, Trager WF The metabolic fate of warfarin: studies on metabolites in the plasma. Ann NY Acad Sci 1971; 179: 205-212.
22. Yacobi A., et al. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 1976; 19: 552-558.
23. Lewis RJ, Trager WF Warfarin metabolism in man: Identification of metabolites in urine. J Clin Invest 1970: 49: 907-913.
24. Blanchard RA, Furrie BC, Jorgensen M., et al. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981; 305: 242-248.
25. Ristola P., Kaleui P. Determinants of the response to coumarin anticoagulants in patients with acute myocardial infarction. Acta Med Scand 1972; 192: 183-188.
26. Ganeval D., Fischer AM, Barre J., et al. Pharmacokinetics of warfarin in nephrotic syndrome and effect on vitamin k-dependent clotting factors. Clin Nephrol 1986; 25: 75-80.
27. Nader HB, Takahashi HK, Straus AH, Dietrich CP Selective distribution of heparin in mammals: conspicuous presence of heparin in lymphoid tissues. Biochim Biophys Acta 1980; 627: 40-48.
28. Straus AH, Nader HB, Dietrich CP Absence of heparin or heparin-like compounds in mast.cell-free tissues and animals. Biochim Biophys Acta 1982; 717: 478-485.
29. Rosenberg RD, Damus PS The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505.
30. Griffith MJ Kinetics of the heparin-enhanced antithrombin III/ thrombin reaction: evidence for a template model for the mechanism of action of heparin. J Biol Chem 1982; 257: 7360-7365.
31. Pomerantz MW, Owen WG A catalytic role for heparin: evidence for a ternary complex of heparin cofactor thrombin and heparin. Biochim Biophys Acta 1978; 535: 66-77.
32. Carlstrom AS, Lieden K., Bjork I. Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin. Thromb Res 1977; 11: 785-797.
33. Larsen AK, Lund DP, Langer R., Folkman J. Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc Nat Acad Sci USA 1986; 83: 2964-2968.
34. Emanuele RM, Fareed J. The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987: 48: 591-596.
35. Briant L., Caranobe C., Saivin S., et al. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost 1989; 61: 348-353.
36. Kandrotas. RJ, Gal P., Douglas JB. Deterding J. Heparin pharmacokinetics during hemodialysis. Ther Drug Monit 1989; 11: 674-679.
37. Kandrotas RJ, Gal P., Douglas JB, Deterding J. Pharmacokinetics and pharmacodynamics of heparin during hemodialysis: interpatient and intrapatient variability. Pharmacotherapy 1990; 10: 349-356.
38. van Rijn JLML, Trilliou M., Mardiguian J., Tobelem G., Caen J. Selective binding of heparins to human endothelial cells: implications for pharmacokinetics. Thromb Res 1988; 49: 373-383.
39. Vannucci S., Pasquali F., Porciatti F., et al. Binding, internalization and degradation of heparin and heparin fragments by cultured endothelial cells. Thromb Res 1988; 49: 373-383.
40. Hiebert LM, McDuffie NM The intracellular uptake and protracted release of exogenous heparins by cultured endothelial cells. Arzery 1989; 16: 208-222.
41. Mastacchi R., Barbanti M. Inactivation of the heparin anticoagulant activity by rat kidney lysosomal enzymes. Thromb Res 1987; 47: 101-106.
42. Proctor RR, Rapaport SI The partial thromboplastin time with kaolin: a simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961: 36: 212-219.
43. Basu D., Gallus A., Hirsh J., Cade J. A prospective study of the value of monitoring heparin treatment with the activated thromboplastin time. N Engl J Med 1972; 287: 324-327.
44. Hull RD, Raskob GE, Hirsh J., et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-1114.
45. Holm HA, Abildgaard U., Kalvenes S., et al. The antithrombotic effect of heparin in deep vein thrombosis: relation to four heparin assays. Acta Med Scand 1984; 216: 287-293.
46. van Putten J., van de Ruit M., Beunis M., Hemker HC Interindividual variation in relationships between plasma heparin concentration and the result of five heparin assays. Clin Chim Acta 1982; 122: 261-270.
47. Teien AN, Lie M. Evaluation of an amidolydic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977: 10: 399-410.
48. Kandrotas RJ, Gal P., Douglas JB, Groce JB Rapid determination of maintenance heparin infusion rates with the use of non-steady-state heparin concentrations. Ann Pharmacother 1993; 27: 1429-1433.
49. Tien AN, Bjornsson J. Heparin elimination in uremic patients on haemo-dialysis. Scand J Haematol 1976; 17: 29-35.
50. Perry PJ, Herron GR, King JC Heparin half-life in normal and impaired renal function. Clin Pharmacol Ther 1974; 16: 514-519.
51. Hirsh J., van Aken WG, Gallas AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53: 691-695.
52. Simon TL, Hyers TM, Gaston JP, Harker LA Heparin pharmacokinetics: increased requirements in pulmonary embolism. Br J Haematol 1978: 11: 111-120.
53. Cipolle RJ, Seifert RD, Neilan BA, Zaske DE, Haus H. Heparin kinetics: variables related to disposition and dosage. Clin Pharmacol Ther 1981; 29: 387-393.
54. Kandrotas RJ, Gal P., Douglas JB, Groce JB, Hansen CJ Altered heparin pharmacodynamics in patients with pulmonary embolism. Ther Drug Monit 1992;14: 360-365.
55. Fareed J., Walenga JM, Hoppensteadt D., Huan X., Nonn R. Biochemical and pharmacologic inequivalance of low molecular weight heparins. Ann NY Acad of Sci 1989; 556: 333-353.
56. Nielsen JI, Ostergaard P. Chemistry of heparin and low molecular weight heparins. Acta Chir Scand 1988; 543: 52-56,.
57. Solandt DY, Best CH Time relations of heparin action on blood clotting and platelet agglutination. Lancet 1940; 233: 1042-1044.
58. Ofosu F., Blajchman MA, Hirsh J. The inhibition by heparin of the intrinsic pathway activation of factor X in the absence of antithrombin-III. Thromb Res 1980: 20: 391-403.
59. Ofosu FA, Modi G., Cerskus AL, Hirsh J., Blajchman MA Heparin with low affinity to antithrombin-III inhibits the activation of prothrombin in normal plasma. Thromb Res 1982; 28: 487-497.
60. Carter CJ, Kelton JG, Hirsh J., et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245.
61. Chiu HM, Hirsh J., Yung WL, Regoeczi E. Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977;49: 171-184.
62. Ockelford PA, Carter CJ, Mitchell L., Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982; 28: 401-409.
63. Bergqvist D., Nilsson B., Hedner U., Pedersen PC, Ostergaard PB The effects of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res 1985; 38: 589-601.
64. Buchanan MR, Boneu B., Ofosu F., Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201.
65. Fareed J., Jeske W., Hoppensteadt D., Clarizio R., Walenga JM Are the available low-molecular-weight heparin preparations the same? Semin Thrombos Hemostas 1996: 22: 77-90.
66. Bara L., Billaud E., Kher A., Samama M. Increased anti-Xa bioavailability for a low molecular weight heparin (PK 10169) compared with unfractionated heparin. Semin Thromb Hemost 1985; 11: 316-7.
67. Emanuele RM, Fareed J. The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987; 48: 591-6.
68. Kandrotas RJ Heparin pharmacokinetics and pharmacodynamics, Clin Pharmacokinet 1992; 22: 359-74.
69. Frydman M., Bara L., Le Roux Y., et al. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin in humans given a single subcutaneous dose of 20-80 mg. J Clin Pharmacol 1988; 28: 609-18.
70. Boneu B., Buchanan MR, Caranobe C., et al. The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard in rabbits. Thromb Res 1987; 46: 845-53.
71. Palm M., Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987; 58: 932-5.
72. Palm M., Mattsson C. Pharmacokinetics of Fragmin: a comparative study in the rabbit of its high and low affinity forms for antithrombin. Thromb Res 1987; 48: 51-62.
73. Bara L., Samama M. Pharmacokinetics of low molecular weight heparins. Acta Chir Scand 1988; 543: 65-72.
74. Dawes J., Bara L., Billaud E., Samama M. Relationship between biological activity and concentration of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration, Haemostasis 1986;16: 116-22.
75. Follea G., Laville M., Pozet N., Dechavanne M. Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure. Haemostasis 1986; 16: 147-51.
76. Goudable C., That HT, Damani A., et al. Low molecular weight heparin half-life is prolonged in haemodialysis patients. Thromb Res 1986; 43: 1-5.
77. Marbet GA, Verstraete M., Kienast J., et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39 393) in healthy volunteers. J Cardiovavc Pharmacol 1993; 22: 364-72.
78. Fox I., Dawson A., Loynds P., et al. Anticoagulant activity of Hirulog™ a direct thrombin inhibitor in humans. Thromb Haemost 1993; 69: 157-63.
79. Stringer KA, Lindenfield J. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992; 26: 1535-40.
80. Markwardt F., Nowak G., Sturzebecher J., Walsman P. Studies on the pharmacokinetics of hirudin. Biomed Biochim Acta 1987; 46: 237-44.
81. Markwardt F., Nowak G., Sturzebecher J., Griesbach U., Walsmann P., Vogel G. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemost 1984; 52: 160-3.
82. Chardot JA, Lefevre GY, Godbillon JA Pharmacokinetics of rechirudin in healthy volunteers after intravenous administration. J Pharmacokin Biopharm 1994: 22: 147-56.
83. Bilcher J., Siebeck M., Fichtl B., Fritz H. Pharmacokinetic effect on clotting tests and assessment of immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man. Haemostasis 1991; 21 (suppl 1):137-141.
84. Nowak G. Pharmacokinetics of hirudin. Semin Thromb Hemost 1991; 17: 145-9.
85. Schiele F., Vuillemenot A., Kramarz P., et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995; 50: 20-25.
86. van den Bos AA, Deckers JW, Heyndrickx GR, et al. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993; 88: 2058-66.
87. Nowak G., Bucha E., Gook TH, Thieler H., Markwardt F. Pharmacology of r-Hirudin in renal impairment. Thromb Res 1992; 66: 707-15.